高级检索
中华实验眼科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 临床研究 •
ENGLISH ABSTRACT
雷珠单抗单次玻璃体腔注射对1型阈值前期和阈值期早产儿视网膜病变的疗效和安全性比较
洪艺洋
李甦雁
刘亚鲁
张正培
季苏娟
刘海洋
作者及单位信息
·
DOI： 10.3760/cma.j.cn115989-20200308-00154
Comparative study on the effect and safety of single intravitreal injection of ranibizumab for type 1 prethreshold and threshold retinopathy of prematurity
Hong Yiyang
Li Suyan
Liu Yalu
Zhang Zhengpei
Ji Sujuan
Liu Haiyang
Authors Info & Affiliations
Hong Yiyang
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
Li Suyan
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
Liu Yalu
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
Zhang Zhengpei
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
Ji Sujuan
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
Liu Haiyang
Department of Ophthalmology, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou Eye Research Institute, Xuzhou 221002, China
·
DOI： 10.3760/cma.j.cn115989-20200308-00154
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的比较早产儿视网膜病变(ROP)的1型阈值前期和阈值期经单次玻璃体腔注射雷珠单抗(IVR)治疗后的疗效、复发率及安全性。

方法采用回顾性队列研究方法，将2016年1月至2019年12月在徐州医科大学附属徐州市立医院接受IVR治疗的ROP患儿51例100眼资料纳入研究。经Retcam眼底照相及间接检眼镜检查确诊1型阈值前期ROP 39例70眼、阈值期ROP 18例30眼。于确诊后24～36 h玻璃体腔注射0.25 mg/0.025 ml雷珠单抗。术后1 d观察有无眼压升高、眼内出血及眼内炎症反应，术后1周用Retcam眼底照相检查眼底病灶是否消退，每间隔2～4周复查1次，直至视网膜血管化，观察有无全身及眼部并发症。比较单次IVR治疗后1型阈值前期和阈值期ROP治愈率、视网膜血管化发生时间及复发率。

结果单次IVR治疗后ROP治愈率为86%(86/100)，均未见全身不良反应，1型阈值前期组、阈值期组ROP治愈率分别为85.71%(60/70)和86.67%(26/30)，2个组比较差异无统计学意义( χ 2＝0.09， P＝0.65)。1型阈值前期组和阈值期组视网膜血管化时间分别为(11.86±8.60)周和(14.45±10.01)周，2个组比较差异无统计学意义( t＝0.88， P＝0.22)。ROP复发10眼，其中1型阈值前期组复发率为5.71%(4/70)，明显低于阈值期组的20.00%(6/30)，差异有统计学意义( χ 2＝4.76， P＝0.03)。10眼ROP复发，其中6眼再次行1次IVR治疗，4眼行1次激光光凝治疗。单次IVR治疗后5眼出现视网膜前出血，未行干预，出血自行吸收。

结论单次玻璃体腔注射雷珠单抗治疗1型阈值前期及阈值期ROP均安全、有效，阈值期组ROP复发率高于1型阈值前期组，经再次治疗可以显著提高治愈率。

早产儿视网膜病变;雷珠单抗;玻璃体腔注射;疗效;安全性
ABSTRACT

ObjectiveTo compare the efficacy, recurrence rate and safety of a single intravitreal injection of ranibizumab between type 1 prethreshold and threshold retinopathy of prematurity (ROP).

MethodsA retrospective cohort study was conducted.A total 100 eyes from 51 ROP patients in Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University from January 2016 to December 2019 were enrolled.Retcam and indirect ophthalmoscope were used to confirm the diagnosis of 39 cases of type 1 prethreshold ROP (70 eyes) and 18 cases of threshold ROP (30 eyes). All the subjects were given a single intravitreal injection of ranibizumab (IVR) 0.25 mg/0.025 ml as the initial treatment within 24-36 hours after diagnosis.Events such as increased intraocular pressure, intraocular bleeding and endophthalmitis were observed and recorded 1 day after IVR.Retcam photography was used to check whether the fundus lesions was subsided 1 week after IVR.Regular follow-up was conducted once every 2-4 weeks until retinal vascularization.Systemic and ocular complications were recorded.The cure rate, the time of retinal vascularization and the recurrence rate of single IVR for type 1 prethreshold disease and threshold disease were compared.This study was approved by the Ethics Committee of Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University.

ResultsAfter a single IVR, 86 of 100 eyes (86.00%) were cured, among which 60 of 70 type 1 prethreshold ROP eyes (85.71%) and 26 of 30 threshold ROP eyes (86.67%) were cured, with no significant difference between the two groups ( χ 2=0.09, P=0.65). No systemic adverse reactions were observed after a single IVR treatment.The final retinal vascularization time was (11.86±8.60) weeks in the type 1 prethreshold ROP group and (14.45±10.01) weeks in the threshold ROP group, with no statistically significant difference between the two groups ( t=0.88, P=0.22). Recurrence of ROP appeared in 10 eyes after a single IVR, including 4 eyes (5.71%) in the type 1 prethreshold ROP group and 6 eyes (20.00%) in the threshold ROP group, the recurrent rate was significantly different between the two groups ( χ 2=4.76, P=0.03). Six recurrent eyes were treated with IVR for the second time, and 4 recurrent eyes were treated with laser photocoagulation.Five eyes presented with preretinal hemorrhage after IVR treatment, and were recovered without intervention.

ConclusionsThe treatment of type 1 prethreshold ROP and threshold ROP with single IVR in vitreous cavity is safe and effective.The recurrence rate of threshold ROP is higher than type 1 prethreshold ROP.Retreatment can significantly improve the cure rate.

Retinopathy of prematurity;Ranibizumab;Intravitreal injection;Therapeutic effect;Safety
Li Suyan, Email: mocdef.6ab216221nayusil
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

洪艺洋,李甦雁,刘亚鲁,等. 雷珠单抗单次玻璃体腔注射对1型阈值前期和阈值期早产儿视网膜病变的疗效和安全性比较[J]. 中华实验眼科杂志,2020,38(06)：522-526.

DOI:10.3760/cma.j.cn115989-20200308-00154

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

早产儿视网膜病变(retinopathy of prematurity，ROP)是发生在早产儿及低体质量儿未发育成熟视网膜的血管性病变，已成为全世界儿童致盲的主要原因之一 [ 1 , 2 ]。研究表明，早产儿视网膜发育不成熟是ROP发病的根本原因 [ 3 , 4 ]。ROP的治疗方法主要有视网膜冷凝和激光光凝以及玻璃体切割术等，其中激光光凝仍是ROP的标准治疗方法，但研究发现激光光凝治疗会导致大范围的视网膜组织破坏，影响患儿视功能预后，且有研究认为激光光凝治疗ROP后患眼近视发生率升高，近视屈光度增加 [ 5 ]。近年来有研究发现，抗血管内皮生长因子(vascular endothelial growth factor，VEGF)药物可抑制患眼组织中VEGF的过量表达，从而减缓眼内新生血管生长，促进视网膜血管向周边部发育，已广泛用于ROP的临床治疗 [ 6 ]。然而，由于ROP患儿视网膜发育不成熟，无论是全身麻醉还是表面麻醉下眼内注射对患儿的生命都有一定的风险，多次手术更增加眼部和全身并发症的风险，因此，以最少的治疗次数达到理想的治疗效果是临床上的目标。目前，雷珠单抗单次注射对于不同程度ROP的疗效仍未十分明确，仍需进一步探讨。本研究探讨单次IVR对1型阈值前期与阈值期ROP的疗效及其安全性。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Zhou Y , Jiang Y , Bai Y ，et al. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab[J]．Graefe's Arch Clin Exp Ophthalmol， 2016，254(1)∶31-36. DOI： 10.1159/000365132 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Gilbert C , Rahi J , Eckstein M ，et al. Retinopathy of prematurity in middle-income countries[J]．Lancet， 1997，350(9070)∶12-14. DOI： 10.1016/s0140-6736(97)01107-0 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Tahija SG , Hersetyati R , Lam GC ，et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone Ⅰ and posterior zone Ⅱ retinopathy of prematurity[J]．Br J Ophthalmol， 2014，98(4)∶507-512. DOI： 10.1136/bjophthalmol-2013-304109 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Cohen SY . Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia[J]．Retina， 2009，29(8)∶1062-1066. DOI： 10.1097/IAE.0b013e3181b1bb1a .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Hsieh CJ , Liu JW , Huang JS ，et al. Refractive outcome of premature infants with or without retinopathy of prematurity at 2 years of age：a prospective controlled cohort study[J]．Kaohsiung J Med Sci， 2012，28(4)∶204-211. DOI： 10.1016/j.kjms.2011.10.010 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
马列，黎晓新．玻璃体腔注射雷珠单抗对增生性糖尿病视网膜病变玻璃体切割术后再出血的防治作用[J]．中华实验眼科杂志， 2017，35(1)∶69-72. DOI： 10.3760/cma.j.issn.2095-0160.2017.01.014 .
返回引文位置Google Scholar
百度学术
万方数据
Ma L , Li XX . Preventive effect of intravitreal injection of ranibizumab on rehaemorrhagia following vitrectomy for prolifarative diabetic retinopathy[J]．Chin J Exp Ophthalmol， 2017，35(1)∶69-72. DOI： 10.3760/cma.j.issn.2095-0160.2017.01.014 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[7]
华文娟，强丽莉，李之喆，等．单胎和多胎早产儿视网膜病变发生率比较及相关因素分析[J]．中华实验眼科杂志， 2015，33(7)∶660-663. DOI： 10.3760/cma.j.issn.2095-0160.2015.07.020 .
返回引文位置Google Scholar
百度学术
万方数据
Hua WJ , Qiang LL , Li ZZ ，et al. Comparison of retinopathy of prematurity incidences between single and multiple premature infants and analysis of related factors[J]．Chin J Exp Ophthalmol， 2015，33(7)∶660-663. DOI： 10.3760/cma.j.issn.2095-0160.2015.07.020 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[8]
Feng J , Qian J , Jiang Y ，et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China[J]．Ophthalmology， 2017，124(3)∶408-409. DOI： 10.1016/j.ophtha.2016.10.032 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Stahl A , Hellstrom A , Smith LE . Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity：has the time come？[J]．Neonatology， 2014，106(3)∶254-260. DOI： 10.1159/000365132 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
中华医学会眼科学分会眼底病学组．中国早产儿视网膜病变筛查指南(2014年)[J]．中华眼科杂志， 2014，50(12)∶933-935. DOI： 10.3760/cma.j.issn.0412-4081.2014.12.017 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Wu WC , Kuo HK , Yeh PT ，et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan[J]．Am J Ophthalmol， 2013，155(1)∶150-158.e1. DOI： 10.1016/j.ajo.2012.06.010 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
方思文，马翔．早产儿视网膜病变的治疗[J]．中华实验眼科杂志， 2020，38(1)∶77-80. DOI： 10.3760/cma.j.issn.2095-0160.2020.01.016 .
返回引文位置Google Scholar
百度学术
万方数据
Fang SW , Ma X ．Treatment on retinopathy of prematurity[J]．Chin J Exp Ophthalmol， 2020，38(1)∶77-80. DOI： 10.3760/cma.j.issn.2095-0160.2020.01.016 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[13]
Kandasamy Y , Kumar P , Hartley L ．The effect of erythropoietin on the severity of retinopathy of prematurity[J]．Eye(Lond)， 2014，28(7)∶814-818. DOI： 10.1038/eye.2014.95 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Chen SN , Lian I , Hwang YC ，et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity：comparison between Ranibizumab and Bevacizumab[J]．Retina， 2015，35(4)∶667-674. DOI： 10.1097/IAE.0000000000000380 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
中华医学会．早产儿治疗用氧和视网膜病变防治指南[J]．中华眼科杂志， 2005，41(4)∶375-376. DOI： 10.3760/j.issn:0412-4081.2005.04.020 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
张海涛，万素华，靳玮，等．康柏西普玻璃体腔注射治疗早产儿视网膜病变的疗效观察及其影响因素分析[J]．中华眼底病杂志， 2019，35(2)∶171-175. DOI： 10.3760/cma.j.issn.1005-1015.2019.02.012 .
返回引文位置Google Scholar
百度学术
万方数据
Zhang HT , Wang SH , Jin W ，et al. Efficacy and related factors of intravitreal injection with conbercept for retinopathy of premature[J]．Chin J Ocul Fundus Dis， 2019，35(2)∶171-175. DOI： 10.3760/cma.j.issn.1005-1015.2019.02.012 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[17]
Huang Q , Zhang Q , Fei P ，et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity：anatomic outcomes and influencing factors[J]．Ophthalmology， 2017，124(8)∶1156-1164. DOI： 10.1016/j.ophtha.2017.03.018 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
李甦雁，Email： mocdef.6ab216221nayusil
B
所有作者均声明不存在利益冲突
C
徐州市卫生杰出人才项目 (XWJC001)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
Lenke 5型青少年特发性脊柱侧凸术后近端交界性后凸发生的相关因素分析
李庆达 等
中华医学杂志 2023,103(29)
视网膜脱离巩膜扣带术后持续性黄斑下液患者视力预后的影响因素
陈燕云 等
中华眼科杂志 2023,59(11)
胸腔积液诊断的中国专家共识
中华医学会呼吸病学分会胸膜与纵隔疾病学组（筹）
中华结核和呼吸杂志 2022,45(11)
巩膜外加压术后出现视网膜下液的危险因素分析及影响
付燕 等
中华眼科杂志 2021,57(06)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大